Molecular and Epidemiological Risk Factors in the Development of Gastric Cancer
Key facts
- Who runs it
- The University of Texas Health Science Center at San Antonio
- Where
- San Antonio, United StatesSee the site
- Trial code
- Status
- Terminated
- People taking part
- 129 people enrolled
- Started
- 22 Jan 2021
- Ended
- 6 Jun 2025
- Type of study
- Observational, 4 groups
- Treatments tested
- Molecular testing for all participants.
- Germline Testing
- Survey
- Record updated
- 14 April 2026
- Why it stopped
- PI leaving institution
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (8)Hide the full registry criteria
Who can take part
- Aged 18 years or older
- Patient with histologically confirmed diagnosis of gastric adenocarcinoma
- Able to understand English or Spanish (only for the prospective cohort)
- GEJ adenocarcinoma Type II (within 1 cm above and 2 cm below the GEJ) and Type III (2-5 cm below the GEJ)
- Hyperplastic polyps
Who cannot take part
- Clinically AND genetically confirmed diagnosis of well-established hereditary cancer syndrome
- Gastroesophageal junction (GEJ) adenocarcinoma Type I (1-5 cm above the GEJ) as they are treated as esophageal cancer
- Other benign or malignant histology types (i.e. leiomyoma, gastrointestinal stroma tumors, fundic gland polyps, etc.)
Where in United States
- Mays Cancer Center, UT Health San AntonioSan Antonio, United States
About the trial
What the trial wants to find out
This protocol is a single-institution feasibility study to identify the molecular and epidemiological risk factors in the development of gastric cancer in high-risk predominantly Hispanic South Texas population. The study is broken down into two main parts: 1) To identify molecular differences in gastric adenocarcinoma (GAC) between Non-Hispanics and Hispanics, stratified by age, and in benign, pre-malignant, and malignant gastric lesions; and 2) To identify environmental and clinicopathological factors in Hispanics associated with specific molecular changes linked to the development of GAC.
The 4 groups in the trial
- Retrospective Non-Hispanics
Molecular testing will be done on formalin fixed paraffin-embeded (FFPE) tissue collected at the time of gastroadenocarcinoma diagnosis and subsequent biopsies. Participants who are alive will be asked to complete a survey and consent to germline testing.
Treatment: Molecular testing for all participants., Germline Testing, and Survey
- Retrospective Hispanic
Molecular testing will be done on formalin fixed paraffin-embeded (FFPE) tissue collected at the time of gastroadenocarcinoma diagnosis and subsequent biopsies. Participants who are alive will be asked to complete a survey and consent to germline testing.
Treatment: Molecular testing for all participants., Germline Testing, and Survey
- Prospective Non-Hispanic
Molecular testing will be done on formalin fixed paraffin-embeded (FFPE) tissue collected at the time of gastroadenocarcinoma diagnosis and subsequent biopsies. Participants will be asked to complete a survey and consent to germline testing.
Treatment: Molecular testing for all participants., Germline Testing, and Survey
- Prospective Hispanic
Molecular testing will be done on formalin fixed paraffin-embeded (FFPE) tissue collected at the time of gastroadenocarcinoma diagnosis and subsequent biopsies. Participants will be asked to complete a survey and consent to germline testing.
Treatment: Molecular testing for all participants., Germline Testing, and Survey
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Identification of Molecular and Epidemiological Risk Factors in the Development of Gastric Cancer in High-risk Predominantly Hispanic Population
- Record updated
- 14 April 2026